These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 26438200)

  • 1. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
    Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
    Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab.
    Guerbau L; Gerard R; Duveau N; Staumont-Sallé D; Branche J; Maunoury V; Cattan S; Wils P; Boualit M; Libier L; Cotteau-Leroy A; Desreumaux P; Nachury M; Pariente B
    Inflamm Bowel Dis; 2017 Oct; 23(10):1853-1859. PubMed ID: 28837519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence of malnutrition and the evolution of nutritional status in patients with moderate to severe forms of Crohn's disease treated with Infliximab.
    Vadan R; Gheorghe LS; Constantinescu A; Gheorghe C
    Clin Nutr; 2011 Feb; 30(1):86-91. PubMed ID: 20719413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy.
    Emerenziani S; Biancone L; Guarino MPL; Balestrieri P; Stasi E; Ribolsi M; Rescio MP; Altomare A; Cocca S; Pallone F; Cicala M
    Dig Liver Dis; 2017 May; 49(5):495-499. PubMed ID: 28096060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
    Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
    J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increases in body mass index during infliximab therapy in patients with Crohn's disease: an open label prospective study.
    Nakahigashi M; Yamamoto T
    Cytokine; 2011 Nov; 56(2):531-5. PubMed ID: 21820319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with infliximab for pediatric Crohn's disease: Nationwide survey of Japan.
    Hosoi K; Ohtsuka Y; Fujii T; Kudo T; Matsunaga N; Tomomasa T; Tajiri H; Kunisaki R; Ishige T; Yamada H; Arai K; Yoden A; Ushijima K; Aomatsu T; Nagata S; Uchida K; Takeuchi K; Shimizu T
    J Gastroenterol Hepatol; 2017 Jan; 32(1):114-119. PubMed ID: 27478130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
    Yu Q; Wang L; Zhang S; Feng T; Li L; Chen B; Chen M
    Blood Transfus; 2016 Sep; 14(5):460-4. PubMed ID: 27136434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for the treatment of Crohn's disease: efficacy and safety in a Chinese single-center retrospective study.
    Zhou Y; He H; Wang P; Zhang T; Lin M; Wang H; Nie Y; Chen Y
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1270-5. PubMed ID: 26275085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
    Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
    J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
    J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative study of induction of remission and cost-effectiveness of enteral nutrition versus infliximab in moderate-to-severe Crohn's disease].
    Zhu WM; Zuo LG; Li Y; Cao L; Zhang W; Gu YF; Xu M; Li N; Li JS
    Zhonghua Nei Ke Za Zhi; 2013 Sep; 52(9):721-5. PubMed ID: 24314158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
    Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
    Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.
    Edlund H; Steenholdt C; Ainsworth MA; Goebgen E; Brynskov J; Thomsen OØ; Huisinga W; Kloft C
    AAPS J; 2017 Jan; 19(1):223-233. PubMed ID: 27739011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.
    Peeters H; Louis E; Baert F; Dewit O; Coche JC; Ferrante M; Lambrecht G; Colard A; Van Gossum A; Bossuyt P; Moreels T; Vander Cruyssen B; Gils A; De Vos M
    Acta Gastroenterol Belg; 2018; 81(1):15-21. PubMed ID: 29562373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease.
    Brown P; Clark T; Dowson G; Warren L; Hamlin J; Hull M; Subramanian V
    J Crohns Colitis; 2016 Oct; 10(10):1144-50. PubMed ID: 26995185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.